The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...
Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...
By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...
After diving over 17% on January 2, shares in biopharma company Intelligent Bio Solutions ($INBS) are back with a rally, ...
Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new ...
Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a one-for-16 reverse stock ...
Investing.com -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) stock fell 21.3% in after-hours trading Wednesday following the company’s announcement of a $10 million private placement with two ...
Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of ...
Investing.com -- Instil Bio (NASDAQ:TIL) stock fell 15% Tuesday after the company announced that its wholly-owned subsidiary Axion Bio has decided to discontinue clinical development of AXN-2510 and ...
Bluebird Bio is short on capital and has major new expenses to cover. Meanwhile, its pipeline of drug candidates is looking very weak. Even if it can navigate the next two years, its growth will be ...
If a little bird told you to think about buying Bluebird Bio (NASDAQ: BLUE) stock recently, there's a lot of information you'll need to evaluate. Between the new product that this small biotech has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback